AltMountain

Cormorant Asset Management, LP

Boston, MA · CRD 167820
Hedge fund manager

Cormorant Asset Management, LP is an SEC-registered investment adviser based in Boston, MA that reports managing 1 hedge fund on Form ADV. It reports $3.8 billion in regulatory assets under management. Its private funds, of all types, hold $3.8 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +11.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +36.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$3.8 billionForm ADV Item 5.F
Gross assets of private funds
$3.8 billionAll private fund types, Form ADV
Hedge funds managed
17 private funds in total
Employees
12Form ADV Item 5.A
Registration
SEC-registered adviserCRD 167820
Latest Form ADV
05/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+11.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+36.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$2.0 billion50 positions, 2026-06-30
$79$108$137Q3 2024Q1 2025Q3 2025Q1 202613F est. $136S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+13.2%+14.8%
Q1 2026-1.9%-4.6%
Q4 2025+33.0%+2.4%
Q3 2025+9.1%+7.8%
Q2 2025+7.1%+10.4%
Q1 2025-24.3%-4.5%
Q4 2024-5.4%+2.1%
Q3 2024+10.4%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 60 share positions ($1,489,258,905) reported by Cormorant Asset Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Parabilis Medicines Inc10.01%
  • Praxis Precision Medicines I9.78%
  • Rapport Therapeutics Inc5.54%
  • Edgewise Therapeutics Inc5.07%
  • Bridgebio Oncology Therapeut4.92%
  • Erasca Inc4.92%
  • Blossomhill Therapeutics Inc4.52%
  • Adlai Nortye LTD4.27%
  • Dianthus Therapeutics Inc2.96%
  • Abivax SA2.83%
StockValue% of 13F portfolioSharesShares vs prior quarter
Parabilis Medicines Inc$149,038,11110.01%4,615,612Unchanged
Praxis Precision Medicines I$145,615,0009.78%500,000-21.88%
Rapport Therapeutics Inc$82,572,7065.54%2,457,521-7.53%
Edgewise Therapeutics Inc$75,516,0005.07%1,860,000-25.90%
Bridgebio Oncology Therapeut$73,302,2354.92%17,878,594Unchanged
Erasca Inc$73,300,0004.92%5,000,000-16.67%
Blossomhill Therapeutics Inc$67,365,5944.52%3,614,034New
Adlai Nortye LTD$63,651,6644.27%3,978,229Unchanged
Dianthus Therapeutics Inc$44,025,0002.96%500,000-33.33%
Abivax SA$42,083,5002.83%425,000-37.04%
Bright Minds Biosciences Inc$39,856,0002.68%800,000-11.11%
Electra Therapeutics Inc$37,862,2492.54%3,365,533New
Moonlake Immunotherapeutics$33,408,5662.24%2,855,433-10.92%
Oruka Therapeutics Inc$33,316,0002.24%400,000-25.00%
Attovia Therapeutics Inc$30,660,2852.06%1,788,815New
Faeth Therapeutics Inc$30,579,9172.05%1,028,242Unchanged
Latigo Biotherapeutics Inc$30,322,8582.04%1,815,740New
Agomab Therapeutics NV$27,365,3631.84%2,465,348Unchanged
Opus Genetics Inc$26,620,0001.79%5,500,000New
Climb Bio Inc$24,155,8201.62%2,106,000Unchanged
Freenome Inc$22,538,7541.51%1,431,032New
MBX Biosciences Inc$21,982,5001.48%375,000-31.82%
Biohaven LTD$20,158,5001.35%1,510,000-42.15%
Adarx Pharmaceuticals Inc$19,200,1761.29%962,898New
Eyepoint Inc$18,802,5001.26%5,750,000-17.86%
Tango Therapeutics Inc$17,465,0001.17%700,000-46.15%
Damora Therapeutics Inc Com SHS$17,024,0001.14%800,000New
Bridgebio Pharma Inc$16,450,0001.10%250,000-54.55%
Cue Biopharma Inc$16,176,1231.09%625,285New
Corbus Pharmaceuticals Hldgs$15,992,7021.07%2,344,971Unchanged
Bioage Labs Inc$15,885,8891.07%2,240,605-6.27%
Alumis Inc$15,334,2501.03%2,075,000-36.85%
Olema Pharmaceuticals Inc$15,120,0001.02%1,750,000-18.60%
Pharvaris N V$14,274,0000.96%450,000-40.00%
Helix Acquisition Corp III$13,779,4500.93%1,297,500Unchanged
Spyre Therapeutics Inc$11,128,7500.75%125,000-44.44%
Definium Therapeutics Inc$10,466,5000.70%275,000-31.25%
Aclaris Therapeutics Inc$9,205,0000.62%1,750,000New
Amylyx Pharmaceuticals Inc$8,730,0000.59%300,000+50.00%
Cabaletta Bio Inc$8,640,0000.58%4,500,000-10.00%
Inhibrx Biosciences Inc$5,004,0000.34%50,000New
Kailera Therapeutics Inc$4,568,0000.31%400,000-27.27%
Jade Biosciences Inc$4,215,0000.28%300,000New
Ibio Inc$4,212,6000.28%3,570,000Unchanged
Tarsus Pharmaceuticals Inc$3,930,5000.26%50,000-50.00%
Roivant Sciences LTD$3,657,0000.25%100,000-78.95%
Enliven Therapeutics Inc$3,438,0000.23%75,000-50.00%
Ascendis Pharma A/s$3,417,4500.23%15,000-70.00%
Odyssey Therapeutics Inc$2,777,5000.19%125,000-28.57%
Newamsterdam Pharma Company$2,432,0000.16%100,000-80.00%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 13 new positions, 3 sold out, 1 increased, 36 reduced and 10 unchanged.

Number of positions (a count, not dollars)

  • New positions13
  • Increased1
  • Unchanged10
  • Reduced36
  • Sold out3

New positions

StockValueShares
Blossomhill Therapeutics Inc$67,365,5943,614,034
Electra Therapeutics Inc$37,862,2493,365,533
Attovia Therapeutics Inc$30,660,2851,788,815
Latigo Biotherapeutics Inc$30,322,8581,815,740
Opus Genetics Inc$26,620,0005,500,000
Freenome Inc$22,538,7541,431,032
Adarx Pharmaceuticals Inc$19,200,176962,898
Damora Therapeutics Inc Com SHS$17,024,000800,000
Cue Biopharma Inc$16,176,123625,285
Aclaris Therapeutics Inc$9,205,0001,750,000
Inhibrx Biosciences Inc$5,004,00050,000
Jade Biosciences Inc$4,215,000300,000
Braveheart Bio Inc$1,414,00070,000

Sold out

StockValue at Jun 30, 2026Shares held then
Damora Therapeutics Inc$26,010,0001,000,000
Crinetics Pharmaceuticals In$4,677,500125,000
Altimmune Inc$3,800,0001,250,000

Largest increases

StockChange in sharesChangeValue nowShares now
Amylyx Pharmaceuticals Inc+100,000+50.00%$8,730,000300,000

Largest reductions

StockChange in sharesChangeValue nowShares now
Praxis Precision Medicines I-140,000-21.88%$145,615,000500,000
Edgewise Therapeutics Inc-650,000-25.90%$75,516,0001,860,000
Abivax SA-250,000-37.04%$42,083,500425,000
Dianthus Therapeutics Inc-250,000-33.33%$44,025,000500,000
Bridgebio Pharma Inc-300,000-54.55%$16,450,000250,000
Tango Therapeutics Inc-600,000-46.15%$17,465,000700,000
Biohaven LTD-1,100,000-42.15%$20,158,5001,510,000
Erasca Inc-1,000,000-16.67%$73,300,0005,000,000
Roivant Sciences LTD-375,000-78.95%$3,657,000100,000
Oruka Therapeutics Inc-133,340-25.00%$33,316,000400,000
MBX Biosciences Inc-175,000-31.82%$21,982,500375,000
Newamsterdam Pharma Company-400,000-80.00%$2,432,000100,000
Pharvaris N V-300,000-40.00%$14,274,000450,000
Alumis Inc-1,210,596-36.85%$15,334,2502,075,000
Spyre Therapeutics Inc-100,000-44.44%$11,128,750125,000
Ascendis Pharma A/s-35,000-70.00%$3,417,45015,000
Rapport Therapeutics Inc-200,000-7.53%$82,572,7062,457,521
Insmed Inc-55,000-73.33%$2,282,80020,000
Bright Minds Biosciences Inc-100,000-11.11%$39,856,000800,000
Definium Therapeutics Inc-125,000-31.25%$10,466,500275,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Rapport Therapeutics, Inc.13G amendment5.12%2,457,521Nov 16, 2026SEC.gov ↗
Opus Genetics, Inc.13G6.61%5,500,000Nov 16, 2026SEC.gov ↗
EyePoint, Inc.13G amendment6.67%5,750,000Nov 16, 2026SEC.gov ↗
Electra Therapeutics, Inc.13G5.36%3,365,533Nov 16, 2026SEC.gov ↗
Bright Minds Biosciences Inc.13G amendment8.11%800,000Nov 16, 2026SEC.gov ↗
Cue Biopharma, Inc.13G9.99%791,377Nov 16, 2026SEC.gov ↗
Cabaletta Bio, Inc.13G amendment2.65%4,500,000Nov 16, 2026SEC.gov ↗
BioAge Labs, Inc.13G amendment4.88%2,240,605Nov 16, 2026SEC.gov ↗
Corbus Pharmaceuticals Holdings, Inc.13G amendment7.76%1,500,000Nov 2, 2026SEC.gov ↗
Rallybio Corp13G amendment0%0Aug 14, 2026SEC.gov ↗
Quince Therapeutics, Inc.13G9.99%108,029Aug 14, 2026SEC.gov ↗
MoonLake Immunotherapeutics13G amendment4.35%3,205,433Aug 14, 2026SEC.gov ↗
iBio, Inc.13G amendment9.99%5,117,481Aug 14, 2026SEC.gov ↗
Adlai Nortye Ltd.13G amendment6.77%3,978,229Aug 14, 2026SEC.gov ↗
BlossomHill Therapeutics, Inc.13D11.79%3,614,034Aug 13, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 24, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 21 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (6)

Fund
Gross assets
Minimum
Owners
Adviser
Cormorant Global Healthcare Master Fund, LP
Cayman IslandsHedge fund
Gross assets$1.9B
Minimum$1.0M
Owners157
AdviserCormorant Asset Management, LP
Cormorant Private Healthcare Fund III, LP
Delaware, United StatesPrivate equity fund
Gross assets$733M
Minimum$5.0M
Owners117
AdviserCormorant Asset Management, LP
Cormorant Private Healthcare Fund IV, LP
Delaware, United StatesPrivate equity fund
Gross assets$499M
Minimum$5.0M
Owners94
AdviserCormorant Asset Management, LP
Cormorant Private Healthcare Fund II, LP
Delaware, United StatesPrivate equity fund
Gross assets$380M
Minimum$5.0M
Owners82
AdviserCormorant Asset Management, LP
Cormorant Private Healthcare Fund V, LP
Delaware, United StatesPrivate equity fund
Gross assets$361M
Minimum$5.0M
Owners40
AdviserCormorant Asset Management, LP
Cormorant Private Healthcare Fund I, LP
Delaware, United StatesPrivate equity fund
Gross assets$125M
Minimum$5.0M
Owners51
AdviserCormorant Asset Management, LP

As reported in the adviser's Form ADV filed May 22, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠